keyword
MENU ▼
Read by QxMD icon Read
search

Biomarker AND parkinson's disease

keyword
https://www.readbyqxmd.com/read/28734065/fdg-pet-dopamine-transporter-spect-and-olfaction-combining-biomarkers-in-rem-sleep-behavior-disorder
#1
Sanne K Meles, David Vadasz, Remco J Renken, Elisabeth Sittig-Wiegand, Geert Mayer, Candan Depboylu, Kathrin Reetz, Sebastiaan Overeem, Angelique Pijpers, Fransje E Reesink, Teus van Laar, Lisette Heinen, Laura K Teune, Helmut Höffken, Marcus Luster, Karl Kesper, Sofie M Adriaanse, Jan Booij, Klaus L Leenders, Wolfgang H Oertel
BACKGROUND: Idiopathic REM sleep behavior disorder is a prodromal stage of Parkinson's disease and dementia with Lewy bodies. Hyposmia, reduced dopamine transporter binding, and expression of the brain metabolic PD-related pattern were each associated with increased risk of conversion to PD. The objective of this study was to study the relationship between the PD-related pattern, dopamine transporter binding, and olfaction in idiopathic REM sleep behavior disorder. METHODS: In this cross-sectional study, 21 idiopathic REM sleep behavior disorder subjects underwent (18) F-fluorodeoxyglucose PET, dopamine transporter imaging, and olfactory testing...
July 22, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28734051/a-user-s-guide-for-%C3%AE-synuclein-biomarker-studies-in-biological-fluids-perianalytical-considerations
#2
REVIEW
Brit Mollenhauer, Richard Batrla, Omar El-Agnaf, Douglas R Galasko, Hilal A Lashuel, Kalpana M Merchant, Lesley M Shaw, Dennis J Selkoe, Robert Umek, Hugo Vanderstichele, Henrik Zetterberg, Jing Zhang, Chelsea Caspell-Garcia, Chris Coffey, Samantha J Hutten, Mark Frasier, Peggy Taylor
Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids. Current knowledge and pitfalls are discussed, and selected perianalytical variables are presented systematically, including different temperature of sample collection and types of collection tubes, gradient sampling, the addition of detergent, aliquot volume, the freezing time, and the different thawing methods...
July 22, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28733961/a-review-of-biomarkers-for-neurodegenerative-disease-will-they-swing-us-across-the-valley
#3
REVIEW
Thomas G Beach
Measures of the severity of cognitive impairment or parkinsonism are the usual endpoints in clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD), but are critically hampered by their lack of disease sensitivity and specificity. Due to the high failure rate of clinical trials, the rate of regulatory approval for efficacious new drugs has stagnated in the past few decades, with the gap between basic science discovery and clinical application metaphorically termed the "Valley of Death". While the causes for this are probably multiple and complex, the usage of biomarkers as surrogate endpoints, particularly when they are molecularly-specific for the disease, has achieved some success in cancer trials, and it is likely that neurodegenerative disease trials would benefit from the same approach...
July 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28731443/accuracy-of-clinical-diagnosis-of-dementia-with-lewy-bodies-versus-neuropathology
#4
Ragnhild E Skogseth, Tibor Hortobágyi, Hogne Soennesyn, Luiza Chwiszczuk, Dominic Ffytche, Arvid Rongve, Clive Ballard, Dag Aarsland
BACKGROUND: The first consensus criteria for dementia with Lewy bodies (DLB) published in 1996 were revised in 2005, partly because the original clinical criteria had suboptimal sensitivity. Few studies have assessed the accuracy of the 2005 criteria applied prospectively in newly diagnosed patients who have been followed longitudinally. OBJECTIVE: To explore the correlation between clinical and pathological diagnoses in patients with DLB and Parkinson's disease with dementia (PDD)...
July 17, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28716280/association-of-polymorphisms-and-reduced-expression-levels-of-the-nr4a2-gene-with-parkinson-s-disease-in-a-mexican-population
#5
Elizabeth Ruiz-Sánchez, Petra Yescas, Mayela Rodríguez-Violante, Nancy Martínez-Rodríguez, Jesica N Díaz-López, Adriana Ochoa, Sergio S Valdes-Rojas, Daniel Magos-Rodríguez, Julio C Rojas-Castañeda, Amin Cervantes-Arriaga, Samuel Canizales-Quinteros, Patricia Rojas
INTRODUCTION: The NR4A2 transcription factor is important in the development, survival and phenotype of dopaminergic neurons and it is postulated as a possible biomarker for Parkinson's disease (PD). Therefore, our aim was to analyze in a sample of a Mexican population with idiopathic PD, mutations (in two hotspot mutation regions) and two polymorphisms (rs34884856 in promotor and rs35479735 intronic regions) of the NR4A2 gene. We also evaluate the levels of NR4A2 gene expression in peripheral blood for a Mexican population, and identify whether they are associated with NR4A2 gene polymorphisms...
August 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28711405/a-unique-glycan-isoform-of-transferrin-in-cerebrospinal-fluid-a-potential-diagnostic-marker-for-neurological-diseases
#6
REVIEW
Kyoka Hoshi, Hiromi Ito, Yuka Matsumoto, Kiyoshi Saito, Takashi Honda, Yoshiki Yamaguchi, Yasuhiro Hashimoto
BACKGROUND: cerebrospinal fluid (CSF) is sequestered from blood by the blood-brain barrier and directly communicates with brain parenchymal interstitial fluid, leading to contain specific biomarkers of neurological diseases. SCOPE OF REVIEW: CSF contains glycan isoforms of transferrin (Tf): one appears to be derived from the brain and the other from blood. MAJOR CONCLUSIONS: CSF contains two glycan-isoforms; brain-type Tf and serum-type Tf...
July 12, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28710399/downregulation-of-blood-serum-microrna-29-family-in-patients-with-parkinson-s-disease
#7
Xiaochen Bai, Yilin Tang, Mei Yu, Lei Wu, Fengtao Liu, Jianliang Ni, Zishan Wang, Jinghui Wang, Jian Fei, Wei Wang, Fang Huang, Jian Wang
There is currently no reliable and easily applicable diagnostic marker for Parkinson's disease (PD). The aims of the present study were to compare the expression profiles of the microRNA29 family (miR-29s) in blood serum from patients with PD with healthy controls and to clarify whether the expression of miR-29s is correlated with disease severity, duration or L-dopa therapy and whether expression depends on the gender and age of patients. The levels of blood serum miR-29s in 80 patients with PD and 80 unaffected controls were assessed by reverse transcription-quantitative real-time PCR...
July 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28709951/microrna-basic-concepts-and-implications-for-regeneration-and-repair-of-neurodegenerative-diseases
#8
REVIEW
Cláudia Saraiva, Marta Esteves, Liliana Bernardino
MicroRNAs (miRNA) are small non-coding molecules that revolutionized our knowledge about the regulation of gene expression. Capable to target a large number of mRNA, miRNA are thought to regulate around 30% of the entire human genome. Therefore, these molecules are able to regulate several biological processes, including neuronal survival, differentiation and regeneration. Additionally, miRNA might act as valuable clinical agents in brain pathological conditions: their specific expression patterns in the brain parenchyma and/or in circulating fluids have been highlighted as potential biomarkers while the modulation of their activity may have therapeutic value for several neurodegenerative diseases...
July 11, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28707023/oxidative-inactivation-of-the-endogenous-antioxidant-protein-dj-1-by-the-food-contaminants-3-mcpd-and-2-mcpd
#9
Thorsten Buhrke, Linn Voss, Anja Briese, Heike Stephanowitz, Eberhard Krause, Albert Braeuning, Alfonso Lampen
3-Chloro-1,2-propanediol (3-MCPD) and 2-chloro-1,3-propanediol (2-MCPD) are heat-induced food contaminants being present either as free substances or as fatty acid esters in numerous foods. 3-MCPD was classified to be possibly carcinogenic to humans (category 2B) with kidney and testis being the primary target organs according to animal studies. A previous 28-day oral feeding study with rats revealed that the endogenous antioxidant protein DJ-1 was strongly deregulated at the protein level in kidney, liver, and testis of the experimental animals that had been treated either with 3-MCPD, 2-MCPD or their dipalmitate esters...
July 13, 2017: Archives of Toxicology
https://www.readbyqxmd.com/read/28705587/diagnosis-of-parkinson-s-disease-and-the-level-of-oxidized-dj-1-protein
#10
Yuko Yamagishi, Kazumasa Saigoh, Yoshiro Saito, Ikuko Ogawa, Yoshiyuki Mitsui, Yukihiro Hamada, Makoto Samukawa, Hidekazu Suzuki, Motoi Kuwahara, Makito Hirano, Noriko Noguchi, Susumu Kusunoki
Parkinson's disease (PD) is difficult to distinguish from progressive supranuclear palsy (PSP) and multiple system atrophy (MSA); in addition, biomarker studies in PD mostly focused on those found in the cerebrospinal fluid, and there are few reports of simple biomarkers identified by blood analysis. Previously, the DJ-1 gene was identified as a causative gene of familial PD. Oxidized DJ-1 protein (oxDJ-1) levels were reported to increase in the blood of patients with unmedicated PD. Therefore, we determined the levels of oxDJ-1 in the erythrocytes of patients with PD, PSP, and MSA using ELISA...
July 10, 2017: Neuroscience Research
https://www.readbyqxmd.com/read/28696436/reduced-trpc6-mrna-levels-in-the-blood-cells-of-patients-with-alzheimer-s-disease-and-mild-cognitive-impairment
#11
R Lu, J Wang, R Tao, J Wang, T Zhu, W Guo, Y Sun, H Li, Y Gao, W Zhang, C J Fowler, Q Li, S Chen, Z Wu, C L Masters, C Zhong, N Jing, Y Wang, Y Wang
Transient receptor potential canonical 6 (TRPC6) inhibits β-amyloid (Aβ) production. Hyperforin, the TRPC6 agonist, reduces Aβ levels and improves cognitive performance in Alzheimer's disease (AD) models. However, it's unknown whether TRPC6 expression is changed in AD patients. In this case-control study, we measured TRPC6 expression levels in the peripheral blood cells of four independent AD sets from five hospitals and one mild cognitive impairment (MCI) set from a local community (229 AD, 70 MCI, 40 Parkinson disease and 359 controls from China, total n=698) using quantitative real-time PCR assay...
July 11, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28695482/role-of-apolipoproteins-and-%C3%AE-synuclein-in-parkinson-s-disease
#12
REVIEW
Fatemeh Nouri Emamzadeh
Parkinson's disease (PD) is a progressive brain disorder that interferes with activities of normal life. The main pathological feature of this disease is the loss of more than 80% of dopamine-producing neurons in the substantia nigra (SN). Dopaminergic neuronal cell death occurs when intraneuronal, insoluble, aggregated proteins start to form Lewy bodies (LBs), the most important component of which is a protein called α-synuclein (α-syn). α-Syn structurally contains hexameric repeats of 11 amino acids, which are characteristic of apolipoproteins and thus α-syn can also be considered an apolipoprotein...
July 10, 2017: Journal of Molecular Neuroscience: MN
https://www.readbyqxmd.com/read/28690499/reduced-circulating-levels-of-mir-433-and-mir-133b-are-potential-biomarkers-for-parkinson-s-disease
#13
Xiong Zhang, Rui Yang, Bei-Lei Hu, Pengcheng Lu, Li-Li Zhou, Zhi-Yong He, Hong-Mei Wu, Jian-Hong Zhu
Aberrant expression of microRNA (miRNA) in tissues may lead to altered level in circulation. Considerable evidence has suggested that miRNA deregulation is involved in the pathogenesis of Parkinson's disease (PD). In this study, we screened a set of PD-associated miRNAs and aimed to identify differentially expressed miRNAs in plasma of PD patients and to evaluate their potentiality to serve as PD biomarkers. A total of 95 subjects consisting of 46 sporadic PD cases and 49 controls were recruited. Plasma levels of six miRNAs including miR-433, miR-133b, miR-34b, miR-34c, miR-153, and miR-7 were evaluated using reverse transcribed quantitative PCR, among which we found that miR-34c and miR-7 were below detection limit under our condition...
2017: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/28686320/the-emerging-science-of-precision-medicine-and-pharmacogenomics-for-parkinson-s-disease
#14
Haydeh Payami
Current therapies for Parkinson's disease are problematic because they are symptomatic and have adverse effects. New drugs have failed in clinical trials because of inadequate efficacy. At the core of the problem is trying to make one drug work for all Parkinson's disease patients, when we know this premise is wrong because (1) Parkinson's disease is not a single disease, and (2) no two individuals have the same biological makeup. Precision medicine is the goal to strive for, but we are only at the beginning stages of building the infrastructure for one of the most complex projects in the history of science, and it will be a long time before Parkinson's disease reaps the benefits...
July 7, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28679601/prospective-clinical-and-dat-spect-imaging-in-premotor-lrrk2-g2019s-associated-parkinson-disease
#15
María Sierra, Isabel Martínez-Rodríguez, Pascual Sánchez-Juan, Isabel González-Aramburu, Mikel Jiménez-Alonso, Antonio Sánchez-Rodríguez, José Berciano, Ignacio Banzo, Jon Infante
OBJECTIVE: To assess the value of baseline clinical and imaging biomarkers in a cohort of asymptomatic LRRK2 G2019S carriers for predicting conversion to Parkinson disease (PD) at 4 years. METHODS: Thirty-two asymptomatic carriers of LRRK2 G2019S mutation underwent baseline and 4-year evaluation including clinical examination (Unified Parkinson's Disease Rating Scale, part III, olfaction University of Pennsylvania Smell Identification Test [UPSIT]) and dopamine transporter (DaT) SPECT ((123)I-ioflupane)...
July 5, 2017: Neurology
https://www.readbyqxmd.com/read/28676787/slowed-prosaccades-and-increased-antisaccade-errors-as-a-potential-behavioral-biomarker-of-multiple-system-atrophy
#16
Sarah H Brooks, Eliana M Klier, Stuart D Red, Neeti D Mehta, Saumil S Patel, Alice Z Chuang, Jessika Suescun, Mya C Schiess, Anne B Sereno
Current clinical diagnostic tools are limited in their ability to accurately differentiate idiopathic Parkinson's disease (PD) from multiple system atrophy (MSA) and other parkinsonian disorders early in the disease course, but eye movements may stand as objective and sensitive markers of disease differentiation and progression. To assess the use of eye movement performance for uniquely characterizing PD and MSA, subjects diagnosed with PD (N = 21), MSA (N = 11), and age-matched controls (C, N = 20) were tested on the prosaccade and antisaccade tasks using an infrared eye tracker...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28674995/biomarkers-in-neurodegenerative-diseases
#17
Andreas Jeromin, Robert Bowser
The past decade has seen tremendous efforts in biomarker discovery and validation for neurodegenerative diseases. The source and type of biomarkers has continued to grow for central nervous system diseases, from biofluid-based biomarkers (blood or cerebrospinal fluid (CSF)), to nucleic acids, tissue, and imaging. While DNA remains a predominant biomarker used to identify familial forms of neurodegenerative diseases, various types of RNA have more recently been linked to familial and sporadic forms of neurodegenerative diseases during the past few years...
2017: Advances in Neurobiology
https://www.readbyqxmd.com/read/28671143/substantia-nigra-neuromelanin-as%C3%A2-an%C3%A2-imaging-biomarker-of-disease-progression-in-parkinson-s-disease
#18
Margherita Fabbri, Sofia Reimão, Miguel Carvalho, Rita G Nunes, Daisy Abreu, Leonor Correia Guedes, Raquel Bouça, Patricia P Lobo, Catarina Godinho, Miguel Coelho, Nilza C Gonçalves, Mario Miguel Rosa, Angelo Antonini, Joaquim J Ferreira
BACKGROUND: A specific T1-weighted magnetic resonance imaging (MRI) sequence has been shown to detect substantia nigra (SN) neuromelanin (NM) signal changes that accurately discriminate Parkinson's disease (PD) patients from controls, even in early disease stages. However, it is unclear what happens to these SN changes in later disease stages and if they can be a marker of disease progression. OBJECTIVE: to investigate the pattern of SN-NM area loss and contrast ratio (CR) intensity changes in late-stage PD (LSPD) compared to earlier disease stages...
June 30, 2017: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/28663000/skewed-x-chromosome-inactivation-and-xist-locus-methylation-levels-do-not-contribute-to-the-lower-prevalence-of-parkinson-s-disease-in-females
#19
Amit Sharma, Oliver Kaut, Anna Pavlova, Holger Fröhlich, Ashar Ahmad, Ina Schmitt, Osman El-Maarri, Johannes Oldenburg, Ullrich Wüllner
Parkinson's disease (PD) is a degenerative disorder of the nervous system and the cause of the majority of sporadic cases is unknown. Females are relatively protected from PD as compared with males and linkage studies suggested a PD susceptibility locus on the X chromosome. To determine a putative association of skewed X-chromosome inactivation (XCI) and PD, we examined XCI patterns using a human androgen receptor gene-based assay (HUMARA) and did not identify any association of skewed or random X inactivation with clinical heterogeneity among female PD patients...
June 6, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28661099/self-administration-of-methamphetamine-alters-gut-biomarkers-of-toxicity
#20
Amanda Flack, Amanda L Persons, Sharanya M Kousik, T Celeste Napier, Anna Moszczynska
Methamphetamine (METH) is a highly abused psychostimulant that is associated with an increased risk for developing Parkinson's disease (PD). This enhanced vulnerability likely relates to the toxic effects of METH that overlap with PD pathology, e.g., aberrant functioning of α-synuclein and parkin. In PD, peripheral factors are thought to contribute to central nervous system (CNS) degeneration. For example, α-synuclein levels in the enteric nervous system (ENS) are elevated, and this precedes the onset of motor symptoms...
June 29, 2017: European Journal of Neuroscience
keyword
keyword
25299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"